Brn-3a neuronal transcription factor functional expression in human prostate cancer

被引：0

作者：

J K J Diss

D J Faulkes

M M Walker

A Patel

C S Foster

V Budhram-Mahadeo

M B A Djamgoz

D S Latchman

机构：

[1] Medical Molecular Biology Unit,Department of Histopathology

[2] Institute of Child Health,Department of Urology

[3] University College London,Department of Cellular and Molecular Pathology

[4] Imperial College School of Medicine,Department of Biological Sciences

[5] St Mary's Hospital,undefined

[6] Imperial College School of Medicine,undefined

[7] St Mary's Hospital,undefined

[8] University of Liverpool,undefined

[9] Neuroscience Solutions to Cancer Research Group,undefined

[10] Imperial College London,undefined

[11] Birkbeck College,undefined

[12] University of London,undefined

来源：

Prostate Cancer and Prostatic Diseases | 2006年 / 9卷

关键词：

Brn-3; real-time PCR; immunohistochemistry; growth; Nav1.7;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Neuroendocrine differentiation has been associated with prostate cancer (CaP). Brn-3a (short isoform) and Brn-3c, transcriptional controllers of neuronal differentiation, were readily detectable in human CaP both in vitro and in vivo. Brn-3a expression, but not Brn-3c, was significantly upregulated in >50% of tumours. Furthermore, overexpression of this transcription factor in vitro (i) potentiated CaP cell growth and (ii) regulated the expression of a neuronal gene, the Nav1.7 sodium channel, concomitantly upregulated in human CaP, in an isoform-specific manner. It is concluded that targeting Brn-3a could be a useful strategy for controlling the expression of multiple genes that promote CaP.

引用

页码：83 / 91

页数：8

共 50 条

[21] Cardiac expression of Brn-3a and Brn-3b POU transcription factors and regulation of Hsp27 gene expression
Farooqui-Kabir, Saleha R.
Diss, James K. J.
Henderson, Deborah
Marber, Michael S.
Latchman, David S.
Budhram-Mahadeo, Vishwanie
Heads, Richard J.
CELL STRESS & CHAPERONES, 2008, 13 (03): : 297 - 312
[22] The POU domain transcription factor Brn-3a protects cortical neurons from apoptosis
Smith, MDP
Ensor, EA
Kinloch, RA
Latchman, DS
NEUROREPORT, 2001, 12 (15) : 3183 - 3188
[23] The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer
Pelzer, AE
Bektic, J
Haag, P
Berger, AP
Pycha, A
Schäfer, G
Rogatsch, H
Horninger, W
Bartsch, G
Klocker, H
JOURNAL OF UROLOGY, 2006, 175 (04): : 1517 - 1522
[24] Gene expression of the POU factor Brn-3a is regulated by two different promoters
Frass, B
Vassen, L
Möröy, T
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2002, 1579 (2-3): : 207 - 213
[25] THE NEURONAL NICOTINIC ACETYLCHOLINE-RECEPTOR ALPHA-2 SUBUNIT GENE PROMOTER IS ACTIVATED BY THE BRN-3B POU FAMILY TRANSCRIPTION FACTOR AND NOT BY BRN-3A OR BRN-3C
MILTON, NGN
BESSIS, A
CHANGEUX, JP
LATCHMAN, DS
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) : 15143 - 15147
[26] THE HUMAN BRN-3B POU TRANSCRIPTION FACTOR SHOWS ONLY LIMITED HOMOLOGY TO THE BRN-3A/RDC-1 FACTOR OUTSIDE THE CONSERVED POU DOMAIN
RING, CJA
LATCHMAN, DS
NUCLEIC ACIDS RESEARCH, 1993, 21 (12) : 2946 - 2946
[27] Neuronal transcription factor BRN2 is an androgen suppressed driver of neuroendocrine differentiation in prostate cancer
Bishop, Jennifer L.
Thaper, Daksh
Vahid, Sepideh
Munuganti, Ravi S.
Ahn, Paul
Davies, Alastair
Ketola, Kirsi
Nip, Ka Mun
Lin, Dong
Wang, Yuzhuo
Beltran, Himisha
Zoubeidi, Amina
CANCER RESEARCH, 2017, 77
[28] Bcl-2 transcription from the proximal P2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor
Smith, MD
Ensor, EA
Coffin, RS
Boxer, LM
Latchman, DS
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) : 16715 - 16722
[29] Functional interaction between the small GTP-binding protein Rin and the N-terminal of Brn-3a transcription factor
Calissano, M
Latchman, DS
ONCOGENE, 2003, 22 (35) : 5408 - 5414
[30] Functional interaction between the small GTP-binding protein Rin and the N-terminal of Brn-3a transcription factor
M Calissano
D S Latchman
Oncogene, 2003, 22 : 5408 - 5414

← 1 2 3 4 5 →